WOMEN’S-ENTREPRENEURSHIP
13.9.2023 20:19:31 CEST | Business Wire | Press release
In alignment with the 78th session of the United Nations General Assembly, the Women’s Entrepreneurship Accelerator (WEA) is proud to announce a pivotal event spotlighting the pressing gap in financing for women-led businesses. This initiative is a collaborative effort with WEA-participating UN agencies, Mary Kay Global, Yildiz Holding, and the Women Entrepreneurs Act initiative (WE Act) of the Women20 (W20) countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913108266/en/
Titled “Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale,” the WEA’s event at UNGA78 is a pivotal event spotlighting the pressing gap in financing for women-led businesses and aiming to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. (Credit: Women’s Entrepreneurship Accelerator)
“Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale”
Conference Room 2, United Nations Headquarters, NYC
Thursday 21 September 2023. Time: 6:00 pm – 8:00 pm ET
Register here
The event aims to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. Discussions will revolve around the financial challenges women entrepreneurs face, the significance of inclusive investing, and the need for institutional and corporate entities to adopt a gender-inclusive perspective in their decision-making processes.
“Through the inception of the Women’s Entrepreneurship Accelerator, Mary Kay has helped carve a new path of intervention for the private sector,” said Deborah Gibbins, Chief Operating Officer, and Chief Financial Officer of Mary Kay Inc. “WEA is a groundbreaking partnership vehicle where the United Nations, public and private sectors, civil society organizations, and policy experts work together to transform the world WITH and FOR women entrepreneurs.”
The evening will commence with welcoming remarks from the executive leadership of UN Women followed by an introduction from Fulya Fraser, Chief Growth Officer at Pladis – part of the Yildiz Holding family of companies.
Two panel sessions will delve deep into the topics at hand:
- Accelerating Agenda 2030 through Women Entrepreneurship - Moderated by Virginia Littlejohn, Global Coordinator for Women Entrepreneurs Act (WE Act) designed to drive W20 action and implementation. The session will explore the "Trillion-dollar Opportunity in Supporting Women Entrepreneurs" and the potential economic impact if women-led businesses surmount financial barriers. Esteemed speakers include executive leaders from WEA UN partner agencies.
- Global Action for Women's Entrepreneurship - This session will spotlight major projects and programs in women entrepreneurship, featuring insights from international development leaders like Adriana Carvalho (W20Brazil), Wendy Teleki (World Bank), Marie-Christine Oghly (Femmes Chefs d’ Entreprise Mondiales - FCEM); Catherine Bosshart (Business and Professional Women - BPW), Anne Ravanona (Global InvestHER), Deborah Gibbins, Mary Kay Global, Lamia Kamal-Chaoui (Organisation for Economic Co-operation and Development - OECD).
The event's keynote will be delivered by Shazi Visram, Founder and CEO of Happy Family brands.
Registration is open until Sunday 17 September 2023 at 11:59 p.m. ET for in-person attendance at the UN Headquarters, NYC. For those unable to attend, the event will be streamed live on the United Nations Web TV website.
For more information and to register, click here.
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-stakeholder partnership on women’s entrepreneurship established during UNGA 74. It convenes six UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), International Telecommunication Union (ITU), United Nations Development Programme (UNDP), United Nations Global Compact (UNGC), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling eco-system for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate. Follow us: Twitter/X (We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913108266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom